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Protein kinase C (PKC) and its proteolysis-derived protein kinase independent of Ca2+ and phospholipids (PKM), were purified from rat brain. 
By using histone Hl and protamine as substrates, we assayed the effect of several inhibitors of PKC and PKM. The inhibition turned out to be 
dependent on both the nature of the kinase and the type of substrate assayed. These results may help to interpret he different responses elicited 
by PKC inhibitors in vivo. 
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1. INTRODUCTION 2.2. Pur@ation of PKC and PKM 
The involvement of protein kinase C (PKC) in the 
transduction of extracellular signals ranging from cell 
proliferation to the control of major metabolic 
pathways in several tissues has stimulated the search for 
activators and inhibitors of the enzyme in order to test 
the p~icipation of this kinase in different biological 
functions [1,2]. The use of phorbol diesters as ac- 
tivators of PKC has proved to be a very useful tool by 
which to study the activation of the enzyme in vivo 
[3,4]. However, regarding the inhibitors, the specificity 
for the inhibition of PKC is not so evident since other 
Gnases also seem to be affected [5,6]. This lack of 
specificity may be overcome by using the inhibitors in 
counteracting the action of specific activators of PKC. 
The study of the effect of the inhibitors on PKC is 
important because in many cases the involvement of 
PKC in a process should be deduced by the effect of its 
inhibitors [6-g]. In the present work, we provide 
evidence suggesting that the results obtained by using 
this approach may be ambiguous ince the action of the 
inhibitors may depend on the nature of the enzyme (the 
native PKC or the proteolysis-derived protein kinase 
M, PKM; [ 10,111) and on the physiological substrate of 
phosphorylation in vivo. 
PKC was purified from rat brain by DE52, phenyiseph~o~ and 
protamine-agarose chromatography as described elsewhere 112,131. 
The specific activity was 950 units/mg protein. PKM was purified 
either by the endogenous activity isolated by DES2 chromatography 
or by in vitro proteolysis of purified PKC. In both cases the enzyme 
was submitted to further purification by phenylsepharose and 
protamine-agarose chromatography, in order to authenticate its iden- 
tity regardless of the origin. To produce PKM in vitro, purified PKC 
(200 units) was incubated with 40 &/ml of rat brain cytosol (1: 3, 
w/v) at 30°C for 30 min in the presence of 0.5 mM CaClz and 
100 ng/ml of phorbol dibutyrate. The reaction mixture was then 
chilled-on ice and applied to a DE52 column (0.5 x 5 cm). After 
washing with buffer A (in mM: 100 NaCl, 10 &mercaptoethanol, 1 
EGTA, 1 EDTA and 10 Hepes, pH 7.5) supplemented with 0.05% 
Nonidet P-40, PKM was eluted in a gradient from 100 to 500 mM 
NaCl in buffer A. PKM activity emerged at 250 mM saIt, and the 
purification was continued by phenylsepharose and protamine- 
agarose chromatography. PKM was applied to the phenylsepharose 
column (0.5 x 5 cm) in buffer A containing 1 M NaCI. The enzyme 
was eluted with buffer A supplemented by 10% glycerol and lacking 
NaCI. Fractions containing activity were pooled and applied to a 
protamineagarose column and eluted with a NaCl gradient in buffer 
A. 
2.3. Assay of PKC and PKM 
2. MATERIALS AND METHODS 
2.1. Chemicals 
[y-“P]ATP (3000 Ci/mol) was from New England Nuclear. 
Sphingosine, H7, gossypol, quercetin and prot~in~ag~ose were 
from Sigma. DES2 was from Whatman. Phenylsepharose was from 
Pharmacia. Other chemicals were from Merck or Boehringer. 
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PKC activity was assayed by the incorporation of [32P]Pi into 
histone Hl in the absence or in the presence of calcium and 
phospholipids as previously described [14]. The assay (lOO$) con- 
sisted of a solution containing in final concentrations 20&M ATP 
(0.1-0.3 &i), 1 mM Mg acetate, 5 mM ~-mer~pt~th~ol, 50 Fg 
histone (type 111s from Sigma), 20 mM Hepes, pH 7.5, and, except 
when otherwise indicated, 0.3 mM CaC12, 10 rglml 
phosphatidylserine and 1 pg/ml dioctanoylglycerol. The reaction was 
stopped by the addition of 2 ml of ice-cold 5% trichloroacetic acid, 
10 mM P04H3. The reaction was linear for at least 20 min. The acid- 
insoluble radioactivity was retained in GFlC filters and counted after 
oven-drying in 2 ml of scintillation cocktail. To qua&ate PKC ac- 
tivity, the incorporation in the absence of Ca” and lipids was sub- 
tracted from the corresponding samples. When protamine was used 
as substrate, the assay was similar to that with histone HI, although 
it contained calcium and lipids considering its relative independence 
of calcium [15]. PKM activity was assayed as described for PKC, but 
in the presence of 0.2 mM EGTA and in the absence of calcium and 
lipids. The use of highly purified PKC and PKM guarantees the 
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validity of the results obtained in these assays. The inhibition cons- 
tant (Ki) for each compound tested was calculated by varying its con- 
centration in the PKC or PKM assay. One unit of PKC or PKM was 
defined as incorporating one nmol of phosphate into the substrate 
per min. Proteins were determined according to the method of Brad- 
ford [16]. 
3. RESULTS 
The effect of several classical inhibitors of PKC was 
tested on both PKC and PKM, using histone Hl or pro- 
tamine as substrates. PKC was purified following stan- 
dard protocols and was highly dependent on the 
addition of Ca*+ and phospholipids. To obtain PKM, 
we used two approaches in establishing the PKC- 
derived origin of this kinase activity: PKM was obtain- 
ed by DE52 chromatography of cytosols from rat brain 
(endogenous PKM), or produced in vitro by proteolysis 
of purified PKC [ 111. Fig. 1 shows the purification of 
PKM from proteolysed PKC, by DE52, phenylse- 
pharose, and by protamine-agarose chromatography. 
PKM was purified basically as PKC with minor changes 
in the elution conditions. However, its different nature 
from PKC is established on the basis of its indepen- 
dence of the activation by Ca*+ and lipids and of the 
different pattern of elution from the DE52 column 
(250 mM NaCl for PKM and 90 mM for PKC), and 
from the protamine-agarose, where by contrast to 
PKM, PKC requires ATP to be eluted [ 121. The specific 
activity of this preparation was 183 units/mg of protein 
which exhibited exactly the same properties as did the 
purified endogenous PKM enzyme. Table I summarizes 
the procedure and the yield for the purification of the 
endogenous PKM. 
Further, to analyze the effect of several PKC in- 
hibitors on both PKC and PKM activities, we used 
histone Hl and protamine as substrates for both en- 
zymes. The relative incorporation of 32P into substrates 
was roughly the same for each kinase. The inhibitors 
used were staurosporine [9], H7 [7], quercetin [ 171, 
gossypol [ 181 and sphingosine [19]. As Table II shows, 
the Ki values for each inhibitor depended on the nature 
of both the kinase and the substrate used to incorporate 
the phosphate. In the case of staurosporine and PKC as 
kinase, a high inhibition was observed either with 
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Table I 
April 1990 
Purification of PKM from rat brain homogenates 
Step Units U/mg protein Yield (Vo) 
DE52 180 0.112 100 
Phenylsepharose 108 0.321 60 
Protamine-agarose 41 182.5 26 
Brains were homogenated and centrifuged at 105000 x g for 30 min. 
The supernatant was incubated at 30°C for 10 min in the presence of 
0.5 mM Ca’+, and purified by DE52, phenylsepharose and 
protamine-agarose chromatography 
Table II 
Inhibition of PKC and PKM by several igands 
Ligand (Ki) PKC PKM 
Histone Protamine Histone Protamine 
Staurosporine (nM) 5.5 12 N.I. N.I. 
H7 GM) 10 17.5 450 500 
Sphingosine (uM) 53 N.I. N.I. N.I. 
Quercetine (rtM) N.I. N.I. 4.5 4.5 
Gossypol (uM) 30 30 190 N.I. 
The enzymes were incubated with the inhibitors prior to starting the 
reaction with [7+3zP]ATP. N.I., not inhibited 
histone or protamine as substrates (Ki = 5.5 and 
12 nM, respectively). However, PKM was not affected 
by staurosporine at concentrations up to 1 PM. In con- 
trast to staurosporine, H7 inhibited PKC assayed either 
with histone or protamine (Ki = lo-20pM), although 
it was less efficient in the inhibition of PKM (Kr = 
400-500 PM). 
A variable pattern of inhibition was observed with 
sphingosine. It was highly effective in the inhibition of 
PKC using Hl as substrate, but failed to inhibit the 
phosphorylation of protamine, and was completely in- 
effective with PKM. Moreover, the incorporation of 
‘*P into protamine was even stimulated in the presence 
of this amino alcohol. 
A specific and potent inhibitor of PKM was 
quercetin, which exhibited Ki values of 4.5 /rM for 
histone and protamine as substrates. However, 
quercetin failed to inhibit PKC in our conditions. This 
is despite the fact that quercetin-related flavonoids 
FRACTION NUMBER 
Fig. 1. Purification of PKM from rat brain. PKM was produced in vitro after proteolysis of purified PKC. The steps were DE52 chromatography 
(A); phenylsepharose (B); and protamine-agarose chromatography, eluted with a gradient of NaCl (0.05-l M) (C). The activity was measured 
using histone Hl as substrate and in the absence (filled symbols) or presence (open symbols) of calcium and lipids. 
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Fig. 2. I~ibition of PKC and PKM by staurosporine and quercetin. 
Purified PKC (0,0) and PKM (A , A) were assayed with histone Hi 
(filled symbols) or with protamine (open symbols) as substrates. 
have been reported to be inhibitors of PKC [17]. Fig. 2 
shows the kinetics of the inhibition by staurosporine 
and quercetin of the activity of PKC and PKM purified 
from rat brain. 
4. DISCUSSION 
The use of in~bitors of PKC has been an effective 
and useful tool by which to ensure its participation in 
several biological processes. The mechanism of action 
of these in~bitors is quite variable, ranging from those 
like H7 that acts on the ATP catalytic site, to 
staurosporine that acts (mainly) on the regulatory do- 
main [2]. Activation of PKC by phorbol esters or via 
enhancement of phosphoinositide turnover in response 
to agonist binding to membrane receptors may be 
prevented, in most cases, by incubating the cells with 
inhibitors such as H7 or staurospo~ne [2,19,20]. A ma- 
jor criticism of the use of these inhibitors is that its 
range of specificity in the inhibition of protein kinases 
is quite broad. However, the unexpected observation 
has been that, in some cases, these inhibitors failed to 
block PKC activation. This is in spite of the very potent 
inhibition of PKC observed in vitro. According to our 
results, the effectiveness of the inhibitors in preventing 
PKC-mediated phosphorylation of intracellular 
substrates may depend on both the nature of these 
substrates and on the relative participation of PKC and 
PKM in the phosphorylation process. This is especially 
relevant in the case of phorbol ester-stimulated cells, 
since these diacylglycerol analogues promote a rapid 
proteolysis of PKC and therefore generate important 
amounts of PKM [21]. Our results may expain the 
failure of some PKC-dependent processes to be af- 
fected by the use of PKC inhibitors. As an example, the 
recent report may be cited showing a differential pat- 
tern of inhibition after topical application of 
staurosporine on phorbol diester-induced skin inflam- 
mation, neutrophil infiltration, epidermal hyperplasia 
or ornithine decarboxylase induction in mouse skin 
[221* 
An ancillary conclusion from our work is that the 
selective employment of inhibitors may be useful to 
analyze the nature of the substrates and the kinase in- 
volved in the activation of the PKC system by specific 
activators such as phorbol esters. The comparison of 
the results obtained after exposure of the cells to ‘selec- 
tive’ inhibitors such as sphingosine, staurosporine and 
quercetin, may provide data concerning the substrate- 
type and kinase that participate in a process elicited by 
PKC activation. 
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